Gepotidacin is an investigational first-in-class oral antibiotic for uncomplicated urinary tract infections. Gepotidacin is active against most strains of target uropathogens, such as E.coli and Staphylococcus saprophyticus, including isolates resistant to current antibiotics. Furthermore, due to gepotidacin’s mechanism of action, blocking bacterial DNA replication by  inhibiting two vital enzymes, mutations in both enzymes are needed to significantly affect susceptibility to gepotidacin. This gives hope that this drug will stay effective as resistance would be harder to develop.